If NUCs protect SARS-CoV-2 infection?

Abstract

We present data from our 4-month research for the effect of Tenofovir, Lamivudine and Entecavir on protection from SARS-CoV-2. We analyzed with rapid antibodies test the status of all patient with liver disease. The total number of examined patients is 478. Their average age is 55,19 ± 12,68. Just 17 from 343 (5%) of those on therapy have antibodies for SARS-CoV-2. 8 from the Tenofovir-treated patients were IgM (+) on a rapid test and 3-IgG (+)(5%). From those on therapy with Lamivudine, 5 were IgM (+) and 1-IgG (+) (6,5%). No patients on Entecavir were positive for IgM or IgG antibodies for SARS-CoV-2.In contrast 14 from 135(10,3%) from the patients without therapy have antibodies. We divided the patients by decades. In almost all decades the percentage of antibodies is two times lower in those on therapy than in those without.